Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Showing of Streams
Showing of Streams
Showing of Streams
12:30pm - 2:10pm

Networking Luncheon, Last Chance for Exhibit and Poster Viewing

Showing of Streams
Showing of Streams
7:30am - 8:00am 30 mins
Scientific Breakfast Briefing #1
In Vivo Platform for Generating Human “Heavy Chain Only” Antibodies for Drug Discovery
  • Frank Grosveld, Ph.D. - Professor of Cell Biology, Erasmus MC, and Founder of Harbour Antibodies BV, Erasmus MC and Harbour BioMed BV
more


The majority of currently approved fully human antibody drugs are generated in vivo from transgenic animal platforms. Here we present recent development from Harbour Antibodies utilizing transgenic mice to generate novel “heavy chain only” antibodies (HCAb). The Harbour HCAb platform enables the development of antibody fragment-based therapeutics such as nanobodies, bi-specific or multivalent antibodies and CAR-T with favorable drug-like properties.


7:30am - 8:00am 30 mins
Scientific Breakfast Briefing #2
FcRn Affinity Column Chromatography
  • Tilman Schlothauer, Ph.D. - Senior Principal Scientist, Roche Innovation Center
more


Fc receptor based affinity chromatography is a new emerging field of Fc functionality analytics. FcRn affinity columns separate antibody species that differ in their affinity to FcRn using conditions that closely resemble the physiological mechanism of IgG and FcRn interaction. This opens up a broad range of new applications using this technology.


8:10am - 8:15am 5 mins
Track 1: Biological Impact of Fc Receptor Engagement
Co-Chairs' Remarks
  • Co-Chair Trudi Veldman, Ph.D. - Senior Director, Biologics, AbbVie Bioresearch Center
  • Co-Chair Chung-Ming Hsieh, D.Sc. - Executive Director, Biologics Discovery Boston, Merck Research Laboratories
more
8:10am - 8:15am 5 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Chairwoman’s Remarks
  • Chairwoman Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
more
8:15am - 8:45am 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases
  • Kenta Haraya, Ph.D. - Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co., Ltd.
more

We generated a novel humanized antibody against C5, SKY59, which has long-lasting neutralization of C5. SKY59 has pH-dependent C5 binding for antibody recycling, and enhanced FcRn binding for PK prolongation without rheumatoid factor (RF) binding.

8:15am - 8:45am 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Strategies to Overcome Immune-inhibition in Childhood Solid Cancers
  • John Anderson, PhD - GOSHCC Professor of Experimental Paediatric Oncology, Honorary Consultant Oncologist, UCL Great Ormond Street Institute of Child Health
more

Immune evasion is a hallmark of cancer, and the solid tumour microenvironment imposes a particularly hostile microenvironment to the immunotherapeutic function of effector cells. Whilst checkpoint inhibition has been a very successful strategy to overcome immune evasion in some cancers with high mutational load, solid cancers lacking strong adaptive immune responses are yet to be shown as sensitive to existing immune modulators. Paediatric cancers largely arise following acquisition of small numbers of mutations during development. Approaches to successful immunotherapy here are likely to require combination approaches of active immunity to target cell surface antigens, and agents to reverse immune evasion.

8:45am - 9:15am 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
Selective FcγR Engagement by Agonistic Anti-CD40 Abs
  • Rony Dahan, Ph.D. - Principal Investigator, Weizmann Institute of Science
more

The engagement of Fcγ Receptors (FcgRs) is required for the in vivo agonistic activity of anti-CD40 immunostimulatory Abs. I will describe the effect of different human FcgRs on the antitumor activity of anti-CD40 human antibodies and how we exploit this knowledge for selection of optimized next-generation Fc-engineered agonistic CD40 Ab.

8:45am - 9:15am 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Co-stimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules
  • Syd Johnson, Ph.D. - Vice President, Antibody Engineering, MacroGenics Inc.
more

Agents that influence immune recognition and elimination of malignant tumor cells generally fall into two classes: those that antagonize immune inhibitory pathways (checkpoint inhibitors) and those that induce immune stimulatory pathways. A limitation of the either mechanism is unwanted immune effects on normal tissues. It is thus highly desirable to limit the immune modulatory activity to the tumor site, while sparing effects on normal cells. To accomplish this in the immune stimulatory context, we have generated bispecific molecules using our Fc-bearing DART and TRIDENT platforms that combine a tumor-specific recognition unit (anti-HER2, EphA2 or other tumor-associated antigen) with a T-cell costimulatory molecule binder (anti-CD137 or other) such that the agonistic activity of the latter is dependent on tumor recognition by the former. In this way not only the tissue localization, but also the agonistic activity, is rendered tumor-dependent, as triggering of the costimulatory molecule by the DART or TRIDENT proteins requires aggregation via tumor target engagement. An optimal level of tumor dependent T-cell agonistic activity was achieved by varying the relative position and valence of each binding site in the molecule. This was easily accomplished within the degrees of variation afforded by the DART/TRIDENT architecture. A case study on the data-driven process for one such molecule will be presented, on this process leading to both a clinical candidate as well as a “plug-and-play” format for facile integration with other tumor antigens. Aspects such as manufacturability, stability and PK will also be addressed.

9:15am - 9:45am 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs
  • Daniel Christ, Ph.D. - Associate Professor, Director Centre for Targeted Therapy, Garvan Institute of Medical Research
more

Interleukin-2 is an established therapeutic agent used for cancer immunotherapy. It is generally believed that treatment efficacy is mediated by CD8+ and NK cell activity, and considerable efforts have focused on generating IL-2 variants that expand these subsets systemically. Here we describe a second and unexpected mechanism, namely the selective depletion of CD25+ CD4+ regulatory T-cells (Tregs), as a major determinant of antitumor activity. Our results outline mechanisms of action and provide important guidance for the development of next generation cytokine therapeutics.

9:15am - 9:45am 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Improved Cancer Immunotherapy by a CD25-mimobody Conferring Selectivity to Human Interleukin-2
  • Natalia Arenas Ramirez, PhD - Post-doctoral Researcher, Department of Immunology, University Hospital Zurich
more

We addressed the most relevant shortcomings associated to IL-2 immunotherapy with the generation of a specific anti-hIL-2 antibody, termed NARA1. In vitro data showed that NARA1 efficiently blocks the CD25 binding site of hIL-2 acting as a high affinity CD25-mimobody.  This resulted in selective stimulation of cytotoxic CD8+ T cells and natural killer cells while keeping low the levels of immunosuppressive Tregs leading to potent anti-tumor responses.

9:45am - 10:30am 45 mins
Track 1: Biological Impact of Fc Receptor Engagement
Networking Refreshment Break, Exhibit and Poster Viewing
9:45am - 10:30am 45 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Networking Refreshment Break, Exhibit and Poster Viewing
10:30am - 11:00am 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
Antibody Optimization for Treg Depletion in Cancer Therapy
  • Frederick Arce Vargas, MD, PhD - Research Associate, University College London Cancer Institute
more

Modulation of the anti-tumor immune response with antibodies targeting co-inhibitory and co-stimulatory molecules is a promising strategy in cancer therapy. In some cases, the effectiveness of these antibodies is not limited to receptor activation or blockade and also relies on depletion of regulatory T cells (Treg). Characterizing the expression density of these targets in different T cell compartments and the myeloid cells involved in Treg depletion is therefore paramount for the design of the next generation of immune-modulatory antibodies.

10:30am - 11:00am 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
ProTIA – Bispecific T Cell Engagers Designed for Local Activation in the Tumor Environment
  • Volker Schellenberger, Ph.D. - CEO and President, Amunix
more

Amunix is developing bispecific T cell engagers based on our proprietary ProTIA (Protease Triggered Immune Activator) platform. ProTIA therapeutics combine multiple mechanisms to widen the therapeutic window: 1) binding to a tumor antigen, 2) proteolytic activation in the tumor environment by tumor-associated proteases, 3) polymer targeting (EPR effect) due to an attached XTEN protein polymer. Most tumor-specific antibodies can be rapidly converted into ProTIA format that enables rapid microbial production as single protein chain. Amunix is currently developing ProTIA molecules against a variety of solid tumor targets. Our lead program AMX-168 is expected to enter clinical development in 2018.ProTIA molecules are based on Amunix’ proprietary XTEN™ polymer technology which has been validated in hundreds of patients and through partnerships with companies such as Biogen, Lilly, Roche, Janssen, Genentech, and Versartis.

11:00am - 11:30am 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity
  • James Ernst, Ph.D. - Senior Scientist & Group Leader, Department of Protein Sciences, Genentech
more

Successful pre-clinical antibody development requires that the molecular properties of therapeutic candidates translate from pre-clinical animal models to humans. For many therapeutic antibodies cytotoxic effector functions can be undesirable, creating safety liabilities by activating native host immune defenses against cells expressing the target antigens. Much research on the attenuation of effector function has focused on ADCC activities of human antibodies as mediated through modifications of the Fc region of the antibody, however, it remains largely unknown how such changes might translate in the context of a murine antibody in mouse models where most therapeutics are validated. We demonstrate that several commonly used variants, which are efficacious in attenuating effector function in primates, retain potent complement activation capacity in mice that can lead to safety liabilities. Here, we describe a novel combination of residue variants that eliminates complement binding and fixation as well as Fcγ dependent antibody-dependent cell-mediated cytotoxicity (ADCC) in both murine IgG2a and human IgG1 - in contrast to the results with aglycosylated antibodies - allowing more accurate translation between experiments in mice and primates. We further demonstrate that both human and murine antibodies containing these variants have typical pharmacokinetics in rodents and retain thermostability. This stability allows for efficient knobs-into-holes bispecific antibody production and a robust path to generating highly effector-attenuated bispecific antibodies for preclinical studies. 

11:00am - 11:30am 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Combining Bi-specific Antibodies and Oncolytic Virus Therapy
  • Shautong Song, M.D., Ph.D. - Chief Executive Officer, Icell Kealex Therapeutics
more

Bi-specific antibody has shown great promise in treatment of cancers. However, its efficacy for solid tumors is significantly limited by its short half-life and suboptimal tumor penetration. In addition, even low levels of tissue expression of tumor associated antigens (TAAs) on normal tissues can be recognized and targeted by bi-specific antibodies leading to deleterious toxicity. Here we described a new strategy to deliver bi-specific antibodies to solid tumors. Oncolytic vaccinia virus has been genetically modified to encode secretory bi-specific T-cell engagers (single chain variable fragment) that bind both to CD3 and to a tumor cell surface antigen. Bi-specific T-cell engager-armed oncolytic vaccinia virus (TEA-VV) exerts its activity through three mechanisms: i) VVs directly lyse tumor cells, ii) TE directs T cells to kill tumor cells that are not infected with VV (by-stander killing), and iii) TE promotes T-cell infiltration into tumors, and the cytokines released upon activation will create a pro-inflammatory microenvironment inhibiting tumor growth. In addition, TEA-VV’s strategy provides a unique and effective approach with the ability of inducing local production of bi-specific antibodies that allows higher concentrations within the tumor tissue while reducing systemic side effects that are caused by BiTE.

11:30am - 12:00pm 30 mins
Track 1: Biological Impact of Fc Receptor Engagement
Novel Engineered Fcs for Improved Half-life Extension and for Highly Selective Engagement of a Single Fcg receptors or C1q
  • George Georgiou, Ph.D. - Professor, Laura Jennings Turner Chair in Engineering, The University of Texas at Austin
more

This presentation will outline several recent advances from our lab on: (i) The engineering of novel Fc domains that impart very long antibody pharmacokinetics; (2) in vitro and in vivo function of antibodies that only activate complement without stimulating signaling via Fcg receptors; (3) the biology and the therapeutic impact of FCRL receptors.

11:30am - 12:00pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment I
Anti-tumor Antibodies Contribute to a Localized Cytokine Storm in the Tumor Microenvironment
  • Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor of Chemical Eng. and Biol. En., Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
more

Classic monoclonal antibodies against anti-tumor associated antigens such as EGFR, CD20, and Her2 synergize with immune oncology therapies such as anti-PD-1 antibodies. One mechanism of action is the vaccinal effect by which anti-TAA antibodies deliver tumor debris to antigen presenting cells for cross presentation. A less well appreciated contribution is through the repolarization of the tumor microenvironment to a more inflammatory state, with significant increases in chemokines and cytokines.

12:00pm - 12:30pm 30 mins
Scientific Briefing 1
Model Aided Drug Invention (MADI) Case Studies: Quantitative Modeling and Simulation Approaches Driving Critical Decisions from Research through Clinical Trials
  • John Burke, PhD - Co-Founder, President, and CEO, Applied BioMath, LLC
more

MADI is a mathematical modeling and engineering approach to translational medicine leveraging mechanistic PKPD and Systems Pharmacology.   It quantitatively integrates knowledge about therapeutics with an understanding of mechanism of action in the context of human disease mechanisms.  We will show how MADI impacts biological understanding, new target proposals, lead generation, clinical candidate selection, IND support, and clinical go/no go decisions. 

12:00pm - 12:30pm 30 mins
Scientific Briefing 2
RESPECT™ (REsidue-SPEcific Conjugation Technology): Site-Specific Conjugation to Lysines in IgG by Microbial Transglutaminase
  • Jared Spidel, Ph.D. - Principal Scientist, Antibody Core Development, Morphotek, Inc.
more

Morphotek’s REsidue SPEcific Conjugation Technology (RESPECT™) is a transglutaminase-based conjugation technology that targets specific lysine residues in IgG.  Whereas other enzymatic-based conjugation techniques require extensive antibody modification by either deglycosylation or addition of multiple-amino acid enzyme-recognition tags, RESPECT™ requires just a single amino acid addition or substitution to efficiently produce homogeneous site-specific antibody conjugates.


12:00pm - 12:30pm 30 mins
Scientific Briefing 3
Automated Antibody Library Construction Using the BioXp™ 3200 System
  • Kurt Klimpel, Ph.D. - Field Application Specialist, Product Development, SGI-DNA
more

Building variant libraries continues to be a highly specialized process and is often outsourced to service labs, which are expensive, have long lead times, and vary in quality. Here, we describe the capability of the BioXp™ 3200 System, the world’s first DNA printer, which allows hands-free, rapid antibody library construction, enabling researchers to engineer antibody segments and introduce mutations for functional studies.

12:30pm - 2:10pm 100 mins
Networking Luncheon, Last Chance for Exhibit and Poster Viewing
2:10pm - 2:15pm 5 mins
Track 1: Novel Therapeutic Indications for Antibodies
Chairman’s Remarks
  • Chairman James Larrick, M.D., Ph.D. - Managing Director and Chief Medical Officer, Velocity Pharmaceutical Development, Panorama Research, Inc.
more
2:10pm - 2:15pm 5 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Chairwoman’s Remarks
  • Chairwoman Janine Schuurman, Ph.D. - Vice President, Research, Genmab
more
2:15pm - 2:45pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Therapeutic Antibodies That Silence B cells by Emulating Peripheral Immune Tolerance
  • John Cambier, PhD - Distinguished Professor and Chair, University of Colorado SOM
more

B cell-targeted therapies whose effects are mediated by B cell depletion have proven efficacious in a variety of autoimmune settings, but have substantial risks due to long-term compromise of adaptive immunity. Here we describe an alternative, non-B cell depleting approach, which employs emasculated antibodies directed against antigen receptor components to induce a reversible state of anergy. This approach has proven effecting in treatment of mouse models of type 1 diabetes, lupus and rheumatoid arthritis.

2:15pm - 2:45pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
RNA Cancer Vaccination and Immunomodulatory Antibodies – Insights from Preclinical Research and Clinical Testing
  • Sebastian Kreiter, M.D. - Director Immune Therapy Development Center, TRON, VP, Immunotherapy and Preclinical Research, BioNTech RNA Pharmaceuticals
more

In vitro transcribed RNA technology is a tool for engineering cancer targeting antibodies as well as for inducing antibody responses by vaccination. In this presentation, I will focus on BioNTech’s preclinical and clinical efforts to generate T- as well as B-cell responses. Moreover, I will discuss data on combination of cancer RNA vaccination with immunomodulatory antibodies.

2:45pm - 3:15pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Development of Anti-MBG Antibody for Hypertension and Fibrosis Diseases
  • Bo Yu, Ph.D. - Co-founder and Chief Scientific Officer, Larix Bioscience LLC
more

Marinobufagenin (MBG) is a cardiotonic steroid (CTS) implicated as a mediator of fibrosis in renal and cardiac diseases. CTS are volume-sensitive hormones that bind to the Na+/K+ -ATPase (NKA) inducing natriuresis. Chronic stimulation of CTS leads to pathological adaptation to volume expansion, including hypertension, hypertrophy, and fibrosis. CTS, particularly MBG, play a critical role in the pathogenesis of hypertension, chronic kidney disease, and preeclampsia. Our study of humanized antibody against MBG has demonstrated neutralizing activities in various in vitro assays and in rodent models.

2:45pm - 3:15pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Imaging to Trace Immunogenic Cell Maturation: Understanding Tumor Microenvironment
  • Edward Roberts, Ph.D. - Scientist, UCSF
more
3:15pm - 3:45pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Targeting APOC3 with a Therapeutic Antibody to Reduce Triglycerides and Risk of Coronary Artery Disease
  • Daniel Rader, M.D. - Seymour Gray Professor of Molecular Medicine, Perelman School of Medicine, University of Pennsylvania
more

Despite aggressive LDL cholesterol reduction, substantial residual risk of coronary heart disease remains. APOC3 is a highly genetically validated therapeutic target for hypertriglyceridemia and cardiovascular disease. We generated a series of monoclonal antibodies, engineered them to extend their half-life, and showed that they markedly reduce triglycerides in a humanized mouse model. Targeting APOC3 with an antibody is an orthogonal approach to reducing LDL cholesterol in addressing residual risk of coronary disease.

3:15pm - 3:45pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members
  • Nick Wilson, Ph.D. - Head of Immuno-Oncology, Gilead Sciences
more

Fc region choice can define the mechanism of action associated with many TNFR superfamily (SF) agonist antibodies. The presentation will cover our recent novel findings in the field of Fc receptor biology and its application to antibodies targeting TNFRSF members. Opportunities to translate lessons learnt into design strategies to more optimally modulate TNFRSF members will also be covered. Emerging data on the role of Fc biology to modulate non-TNFSF receptors will also be discussed.

3:45pm - 4:15pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Networking Refreshment Break
3:45pm - 4:15pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Networking Refreshment Break
4:15pm - 4:45pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Reversal of Acute Type 1 Diabetes with An Anti-TLR4/MD-2 Monoclonal Antibody
  • William Ridgway, M.D. - Professor, University of Cincinnati
more

We have reversed new onset type 1 diabetes (T1D) (hyperglycemia, polyuria and weight loss) in nonobese diabetic (NOD) mice by treatment with an agonistic TLR4/MD-2 specific monoclonal antibody (“TLR4-Ab”). 90% of mice treated with TLR4-Ab showed a clinical response (delay in progression to endstage T1D) and 70% have permanent reversal of T1D. Successfully treated mice demonstrate decreased islet inflammation and preserved insulin staining of islet beta cells. Although TLR4-Ab does not stimulate T cells directly, immune tolerance can be restored to the adaptive immune system by this treatment. The TLR4/MD-2 pathway is a promising new therapeutic approach for treating autoimmunity.

4:15pm - 4:45pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Daratumumab, An IgG1 CD38 Antibody, Reduces Immune Suppressive Cells and Promotes An Adaptive Immune Response in Multiple Myeloma: Potential for Application in Solid Tumors
  • Kate Sasser, Ph.D. - Corporate Vice President, Biomarkers and Diagnostics, Genmab US, Inc.
more

Daratumumab (DarzalexTM), a CD38 antibody approved for treatment of relapsed/refractory myeloma, demonstrated impressive clinical response rates and improved progression free and overall survival in patients treated with this therapy. Correlative studies revealed that along with rapid tumor cell reduction, Daratumumab is also able to significantly reduce CD38+ immune suppressive cells that are prevalent in the tumor microenvironment and contribute to progressive immune dysfunction. Regulatory B cells (Bregs) and myeloid derived suppressor cells (MDSC) express CD38 at high levels, as do a subpopulation of regulatory T cells (Tregs). These CD38+ immune suppressive cells were susceptible to Daratumumab in vitro, and patients treated with Daratumumab exhibited a marked reduction in theses cell types. In parallel, Daratumumab promoted an expansion of CD8+ cytotoxic T cells, and a significant increase in T cell repertoire (TCR) clonality. These data suggest that Daratumumab may have broad immune modulatory activity within the tumor microenvironment, through targeting of CD38+ immune suppressive cellular populations and increasing adaptive immune responses. This mechanism of action may expand the potential application of Daratumumab beyond myeloma therapy, and is currently being investigated in translational and clinical studies.

4:45pm - 5:15pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Action of Bispecific Anti-FGFR1/βKlotho Antibody in Obese Mice and Humans
  • Junichiro Sonoda, Ph.D. - Senior Scientist, Cancer Immunology, Genentech, Inc.
more

FGF21 analogs belong to an emerging class of therapeutic candidates for type 2 diabetes and fatty liver disease. We have engineered bispecific anti-FGFR1/βKlotho agonist antibody that acts as a long-acting FGF21-mimetic. I will present the mechanism of antibody action, together with the results from the first-in-human study performed with obese human subjects.

4:45pm - 5:15pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
Target Expression, Generation, Mechanism of Action, Preclinical Activity and Pharmacokinetics of EM801, an IgG-based BCMA T-cell Bispecific Antibody for the Treatment of Multiple Myeloma
  • Dirk Hose, M.D. - Head, Multiple Myeloma Research Laboratory, Department of Internal Medicine, Heidelberg University
more

We assessed BCMA as target for T-cell immunotherapy and generated/evaluated the BCMA-TCB EM801 for treatment of multiple myeloma, a malignant plasma cell disease. We identified BCMA as excellent target, including high-risk/refractory patients. EM801 shows high single agent activity, even in heavily-pretreated patients, without significant toxicity. Together with a weekly administration schedule, EM801 appears as attractive non-cross-resistant compound with high potential for single agent, combination, or long-term maintenance treatment in myeloma.

5:15pm - 5:45pm 30 mins
Track 1: Novel Therapeutic Indications for Antibodies
Therapeutic Targeting of Notch 3 Signaling for Cerebral Small Vessel Disease
  • Joseph Arboleda-Velasquez, MD, PhD - Assistant Professor, Harvard Medical School
more

Preclinical studies showed the feasibility of targeting mural cell survival by using modulating antibodies capable of activating Notch 3 signaling. We will discuss implications of this work for prevalent causes of mural cell degeneration including diabetic retinopathy and cerebral small vessel disease.


5:15pm - 5:45pm 30 mins
Track 2: Antibody Based Innovations in the Tumor Microenvironment II
An EGFR-targeting Probody™ T cell-engaging Bispecific Induces Tumor Regressions While Reducing On-target Toxicities in Preclinical Studies
  • Leila Boustany, PhD - Senior Scientist I, Cancer Immunology, CytomX Therapeutics
more

In the tumor microenvironment, protease activity is highly dysregulated, enabling tumor cell migration, invasion and metastasis, while in normal tissues, proteases are tightly controlled. By exploiting this differential, we have engineered a protease-activatable Probody T cell-engaging bispecific (Pb-TCB) targeting EGFR that effectively regresses tumors in mice and significantly reduces EGFR-dependent, and immune-mediated, toxicities in healthy tissues of cynomolgus monkeys. By localizing their activity to the tumor microenvironment, Probody TCBs have the potential to expand the target landscape for this potent modality in solid tumors.

5:45pm - 6:45pm 60 mins
Special Session of the Antibody Society
Special Session of the Antibody Society: The WHO INN Program Scope and Policies
  • Moderator Janice Reichert, Ph.D. - Editor-in-Chief / Executive Director / Managing Director, mAbs / The Antibody Society / Reichert Biotechnology Consulting LLC
  • Speaker Raffaella Balocco Mattavelli, PhD - Group Lead, INN, Essential Medicines and Health Products, World Health Organization (WHO)
more

Featured Speaker:

The WHO INN Program Scope and Policies

Raffaella Balocco Mattavelli, Ph.D., Group Lead, INN, Essential Medicines and Health Products, World Health Organization (WHO), Switzerland